Breaking News

Biotium Debuts Novel Fluorescent Dyes that Push Emission Further into the Infrared Spectrum

New CF®850 and CF®870 dyes mark the first commercially available fluorescent dyes with emission beyond 850 nm.

New Water Preservation Cell Promotes Elimination of Water-borne Contaminants in Laboratory Incubators for Increased Productivity

This product is only available in the UK, Ireland, Germany, France, Austria, Switzerland, Sweden, Finland and Iceland.

Improve Your Cell Viability with INTEGRA Liquid Handling Solutions

This equipment is designed to offer enhanced pipetting speed control, limiting the stress placed on cells during handling to improve cell viability.

New Acquisitions & Mergers

Enveric Biosciences Announces Closing of MagicMed Industries Acquisition

Enveric intends to immediately accelerate the development of a novel Psychedelic molecule for Cancer Related Distress.

Insightful Science Acquires FCS Express

FCS Express expands the flow cytometry solutions within the Insightful Science platform, enabling world-class data-driven scientific research in academia and biopharma and clinical analysis in regulated enterprise environments. Insightful Science is the leading end-to-end scientific research platform with both the broadest and deepest scientific capabilities across chemistry and biology. The unique platform accelerates innovation and drug discovery by producing a seamless flow of clean and trustworthy data throughout labs.

Growth / Development

54gene Closes $25M Series B

The round also included participation from Adjuvant Capital, KdT Ventures, Plexo Capital, Endeavor Capital, Ingressive Capital and others.

Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases

Novel drug-development approach combines advanced insights into critical neuronal cell pathways with cutting-edge assays to enable next-generation therapies.

Clinical Trials

Pulmotect Reports Positive Topline Results from Randomized, Placebo Controlled Phase-2 Trial of PUL-042 Against COVID-19

Statistically significant reduction in time to the improvement of respiratory symptoms. Fewer hospitalizations and intensive care admissions

Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021

The study is being conducted in collaboration with Vanderbilt University Medical Center in the U.S. under the direction of Daniel Claassen, MD, Associate Professor of Neurology and Principal Investigator.

Executives on the Move

Camilla Soenderby Appointed to F2G Board of Directors

Francesco Maria Lavino, CEO of F2G Ltd, added: "Camilla's experience and successful track record in rare diseases will be invaluable as we look to maximise the potential of olorofim.

Cumulus Neuroscience Appoints Dr. Ruth McKernan CBE as Chair

Ruth McKernan, newly appointed Chair added: “The formation of Cumulus Neuroscience represents a significant opportunity to address some of the current limitations of clinical trials in dementia and other brain disorders.

Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences’ Board of Directors

Chip Clark, Genocea’s President, and Chief Executive Officer said, "As we advance our pipeline, including GEN-011, our neoantigen-targeted T cell therapy for the treatment of solid tumors, we believe Jennifer’s deep industry and commercial expertise will prove invaluable to us."

FDA Cleared Devices & News

Co-Diagnostics JV CoSara Receives Clearance from Indian FDA for Chikungunya and Dengue Tests

The Saragene test kits approved by the CDSCO use the Company's patented CoPrimer™ technology for the qualitative detection of these mosquito-borne viruses.

FDA Clears Promega OncoMate™ MSI Dx Analysis System

Oncologists and pathologists in US can now use microsatellite instability (MSI) diagnostic to screen for Lynch syndrome in patients with colorectal cancer.


AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn’s Disease

"While there have been advancements in care, many people with Crohn's disease do not achieve lasting remission," said Tom Hudson, senior vice president of research and development, chief scientific officer, AbbVie. "This submission is an important step forward in our commitment to providing an additional treatment option for those who struggle with this debilitating and often unpredictable disease."

Biophytis Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 COVA Study With Sarconeos (BIO101) in COVID-19

The second Interim Analysis based on 155 hospitalized patients shows no futility, with efficacy results in the promising zone, indicating that BIO101 remains a candidate treatment for acute respiratory failure associated with COVID-19.